Email this article 
Photodynamic therapy for mycosis fungoides: a case series and review of the literature
- Authors: Hunger R.E. 1, Sallam M. 1, Yawalkar N. 1
- Affiliations:
- University of Bern
- Issue: Vol 91, No 1 (2015)
- Pages: 24-31
- Section: EDITORIAL
- URL: https://vestnikdv.ru/jour/article/view/101
- DOI: https://doi.org/10.25208/0042-4609-2015-91-1-24-31
Abstract
Mycosis fungoides (MF) is the most common form of cutaneous T cell lymphoma. In early stages of the disease, topical therapeutic approaches like steroids, chemotherapy, phototherapy or spot radiation therapy are most commonly used. Photodynamic therapy (PDT) is widely executed in the treatment of actinic keratosis and superficial basal cell carcinoma. The effective use of PDT for early forms of MF has been previously demonstrated in a series of cases. In this instance, the treatment of MF (n = 6, 11 lesions) with methyl alanine PDT (MAL-PDT) in 73% of the treated lesions showed a complete response. Within the timeframe of 25-51 months, no recurrence of the successfully treated lesions was observed, on the contrary some of the patients developed new lesions on different sites. Hence, this case study shows that patients having a single or few MF lesions can be successfully treated by PDT.
About the authors
Robert E. Hunger
University of Bern
Author for correspondence.
Email: robert.hunger@insel.ch
Russian Federation
Mohamed Sallam
University of Bern
Email: noemail@neicon.ru
Russian Federation
Nikhil Yawalkar
University of Bern
Email: noemail@neicon.ru
Russian Federation
References
- Willemze R., Jaffe E.S., Burg G., Cerroni L., Berti E., Swerdlow S.H. et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-85. Epub 2005/02/05.
- Jawed S.I., Myskowski P.L., Horwitz S., Moskowitz A., Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. Journal of the American Academy of Dermatology. 2014; 70(2): 205 e1-16; quiz 2І-2. Epub 2014/01/21.
- Jawed S.I., Myskowski P.L., Horwitz S., Moskowitz A., Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part II. Prognosis, management, and future directions. Journal of the American Academy of Dermatology. 2014; 70(2): 223 e1-17; quiz 40-2. Epub 2014/01/21.
- Willemze R., Dreyling M. Primary cutaneous lymphomas: ESmO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2010;21 Suppl 5:v177-80. Epub 2010/06/29.
- Braathen L.R., Szeimies R.M., Basset-Seguin N., Bissonnette R., Foley P., Pariser D. et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. Journal of the American Academy of Dermatology. 2007;56(1):125-43. Epub 2006/12/28.
- Wennberg A.M. Pain, pain relief and other practical issues in photodynamic therapy. The Australasian journal of dermatology. 2005; 46 Suppl 3:S3-4; discussion S23-5. Epub 2005/04/30.
- Warren C.B., Karai L.J., Vidimos A., Maytin E.V. Pain associated with aminolevulinic acid-photodynamic therapy of skin disease. Journal of the American Academy of Dermatology. 2009;61(6):1033-43. Epub 2009/11/21.
- Wolf P., Fink-Puches R., Cerroni L., Kerl H. Photodynamic therapy for mycosis fungoides after topical photosensitization with 5-aminolevulinic acid. Journal of the American Academy of Dermatology. 1994;31(4):678-80. Epub 1994/10/01.
- Edstrom D.W., Porwit A., Ros A.M. Photodynamic therapy with topical 5-aminolevulinic acid for mycosis fungoides: clinical and histological response. Acta dermato-venereologica. 2001; 81(3): 184-8. Epub 2001/09/18.
- Edstrom D.W., Hedblad M.A. Long-term follow-up of photodynamic therapy for mycosis fungoides. Acta dermato-venereologica. 2008; 88(3): 288-90. Epub 2008/05/16.
- Zane C., Venturini M., Sala R., Calzavara-Pinton P. Photodynamic therapy with methylaminolevulinate as a valuable treatment option for unilesional cutaneous T-cell lymphoma. Photo-dermatology, photoimmunology & photomedicine. 2006; 22(5): 254-8. Epub 2006/09/05.
- Kim S.T., Kang D.Y., Kang J.S., Baek J.W., Jeon Y.S., Suh K.S. Photodynamic therapy with methyl-aminolaevulinic acid for mycosis fungoides. Acta dermato-venereologica. 2012; 92(3): 264-8. Epub 2011/12/16.
- Quereux G., Brocard A., Saint-Jean M., Peuvrel L., Knol A.C., Allix R. et al. Photodynamic therapy with methyl-aminolevulinic acid for paucilesional mycosis fungoides: a prospective open study and review of the literature. Journal of the American Academy of Dermatology. 2013; 69(6): 890-7. Epub 2013/09/18.
- Rubel D.M., Spelman L., Murrell D.F., See J.A., Hewitt D., Foley P. et al. Daylight PDT with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional PDT in actinic keratosis treatment: a randomised controlled trial. The British journal of dermatology. 2014. Epub 2014/05/28.
- Wiegell S.R., Wulf H.C., Szeimies R.M., Basset-Seguin N., Bissonnette R., Gerritsen M.J. et al. Daylight photodynamic therapy for actinic keratosis: an international consensus: International Society for Photodynamic Therapy in Dermatology. Journal of the European Academy of Dermatology and Venereology: JEADV. 2012; 26(6): 673-9. Epub 2012/01/04.